Viral hepatitis and human immunodeficiency virus co-infections in Asia

doi:10.5501/wjv.v4.i2.96

Advanced Search

BPG is committed to discovery and dissemination of knowledge

Home / Archive / Volume 4, Issue 2

This Article

Academic Content and Language Evaluation of This Article

CrossCheck and Google Search of This Article

Academic Rules and Norms of This Article

Citation of this article

Corresponding Author of This Article

Research Domain of This Article

Article-Type of This Article

Open-Access Policy of This Article

Times Cited Counts in Google of This Article

Number of Hits and Downloads for This Article

Total Article Views (8506)

All Articles published online

The chart showing PDF series, WORD series, HTML series, Tables (1-2) series.

Item

Count

PDF

528

WORD

315

HTML

4173

Tables (1-2)

234

Sum=5250

Publishing Process of This Article

The chart showing Browse series, Download series.

Item

Count

Browse

1393

Download

1863

Sum=3256

May 12, 2015 (publication date) through Jul 27, 2024

Times Cited of This Article

Times Cited (19)

Journal Information of This Article

Publication Name

World Journal of Virology

ISSN

2220-3249

Publisher of This Article

Baishideng Publishing Group Inc, 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA

Review

World J Virology. May 12, 2015; 4(2): 96-104
Published online May 12, 2015. doi: 10.5501/wjv.v4.i2.96

Table 2 Antiretroviral therapies for hepatitis B virus/human immunodeficiency virus co-infection, and drug-resistant mutations in Asian countries

	Indonesia	Japan	Thailand	Vietnam	China	India
Recommendation for ART on HBV/HIV co-infection	Initiate with WHO clinical stage IV and/or a CD4 count less than 200/mm^3[40]	TDF + 3TC/FTC-based regimen	Screening for HBV. Two antiretroviral regimen with anti-HBV/anti-HIV activity (e.g., TDF, 3TC)	TDF-based regimen	Combination of TDF with FTC or 3TC	HBeAg positivity is indicator to initiate ART with combination of two dually-active drugs
Currently used therapy for HBV/HIV co-infection	Telbivudine (LDT) Lamivudine (3TC) Zidovudine (ZDV) Nevirapine (NVP) Efavirenz (EFV) Stavudine (d4T) Tenofovir (TDF)	3TC Entecavir (ETV) TDF Adefovir dipivoxil (ADV) Emtricitabine (FTC)	3TC Nevirapine (NVP) EFV Stavudine (d4T)	Stavudine (d4T) 3TC NVP	d4T ZDV 3TC NVP EFV[41]	ZDV 3TC NVP EFV d4T[42]
Drug-resistant mutation	Lamivudine M204I M204I + L180M	Lamivudine¹V173L + L180M + M204V Lamivudine L180M, M204V, L217R M184V, I195M	Lamivudine M204V/I	Lamivudine L180M M204V		Lamivudine¹M204VL180M

¹Lamibudin naïve case. WHO: World Health Organization; HBV: Hepatitis B virus; HIV: Human immunodeficiency virus; FTC: Emtricitabine; TDF: Tenofovir; LDT: Telbivudine; ETV: Entecavir; ZDV: Zidovudine; ADV:Adefovir dipivoxil; NVP: Nevirapine.

Citation: Utsumi T, Lusida MI. Viral hepatitis and human immunodeficiency virus co-infections in Asia. World J Virology 2015; 4(2): 96-104
URL: https://www.wjgnet.com/2220-3249/full/v4/i2/96.htm
DOI: https://dx.doi.org/10.5501/wjv.v4.i2.96